Recurrence‐free survival after hepatectomy using propofol‐based total intravenous anaesthesia and sevoflurane‐based inhalational anaesthesia: a randomised controlled study
Primary result · Recurrence-free survivalResult — go to the resultAHR for recurrence or death 1.04 95% CI 0.72–1.52Authors' conclusion
Intra-operative anaesthesia technique did not affect postoperative recurrence and overall survival in patients with hepatocellular carcinoma undergoing hepatectomy.
Study context
- Population
- Adults scheduled for elective hepatectomy for hepatocellular carcinoma
- Participants
- 228 vs 226
- Comparison
- Propofol-based TIVA vs sevoflurane-based inhalational anaesthesia
- TIVAn = 228
- Sevofluranen = 226reference
- Primary endpoint
- Recurrence-free survival
- Follow-up
- One year
Primary result
As reported in the abstract
AHR for recurrence or death
1.04
95% CI 0.72–1.52
Events by treatment group
TIVA vs Sevoflurane
aHR for recurrence or death 1.04 (95% CI 0.72–1.52)
Further findings
Intrahepatic recurrence-free survival · one year
Extrahepatic recurrence-free survival · one year
Overall survival · one year
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Recurrence or death, open hepatectomy (subgroup) | 0.49 (0.25–0.95) | P = 0.034 | |
| Recurrence or death, laparoscopic surgery (subgroup) | 1.14 (0.73–1.80) | P = 0.558 | |
| 0.20.5125Hazard ratio (log scale) |
Intrahepatic recurrence-free survival · one year
- Not significantly different
Extrahepatic recurrence-free survival · one year
- Not significantly different
Overall survival · one year
- Not significantly different
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Recurrence‐free survival after hepatectomy using propofol‐based total intravenous anaesthesia and sevoflurane‐based inhalational anaesthesia: a randomised controlled study. Anaesthesia. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →